RT Journal Article
SR Electronic
T1 Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.23.20247379
DO 10.1101/2020.12.23.20247379
A1 Tom, Jennifer
A1 Bao, Min
A1 Tsai, Larry
A1 Qamra, Aditi
A1 Summers, David
A1 Carrasco-Triguero, Montserrat
A1 McBride, Jacqueline
A1 Rosenberger, Carrie M
A1 Lin, Celia J F
A1 Stubbings, William
A1 Blyth, Kevin G
A1 Carratalà, Jordi
A1 François, Bruno
A1 Benfield, Thomas
A1 Haslem, Derrick
A1 Bonfanti, Paolo
A1 van der Leest, Cor H
A1 Rohatgi, Nidhi
A1 Wiese, Lothar
A1 Luyt, Charles Edouard
A1 Kheradmand, Farrah
A1 Rosas, Ivan O
A1 Cai, Fang
YR 2020
UL http://medrxiv.org/content/early/2020/12/26/2020.12.23.20247379.abstract
AB Background Retrospective observational studies suggest that interleukin-6 (IL-6), C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, lymphocytes, monocytes, neutrophils, D-dimer, and platelets are associated with disease progression, treatment outcomes, or both, in patients with COVID-19 pneumonia. We explored these candidate prognostic and predictive biomarkers with efficacy outcomes after treatment with tocilizumab, an anti–IL-6 receptor antibody using data from the COVACTA trial for patients hospitalised with severe COVID-19 pneumonia.Methods Candidate biomarkers were measured in 295 patients in the tocilizumab arm and 142 patients in the placebo arm. Efficacy outcomes assessed were clinical status on a seven-category ordinal scale (1, discharge; 7, death), mortality, time to hospital discharge, and mechanical ventilation (if not receiving it at randomisation) through day 28. Prognostic and predictive biomarkers were evaluated continuously with proportional odds, binomial or Fine-Gray models, and additional sensitivity analyses.Findings Modelling in the placebo arm showed all candidate biomarkers except LDH and D-dimer were strongly prognostic for day 28 clinical outcomes of mortality, mechanical ventilation, clinical status, and time to hospital discharge. Modelling in the tocilizumab arm showed a predictive value of ferritin for day 28 clinical outcomes of mortality (predictive interaction p=0.03), mechanical ventilation (predictive interaction p=0.01), and clinical status (predictive interaction p=0.02) compared with placebo.Interpretation Multiple biomarkers prognostic for clinical outcomes were confirmed in COVACTA. Ferritin was identified as a predictive biomarker for the effects of tocilizumab in the COVACTA patient population; high ferritin levels were associated with better clinical outcomes for tocilizumab compared with placebo at day 28.Evidence before this study The efficacy and safety of the anti–interleukin-6 receptor antibody tocilizumab in the treatment of patients hospitalised with COVID-19 pneumonia was investigated in COVACTA, a double-blind, randomised, placebo-controlled trial. The primary endpoint of improved clinical status on a seven-category ordinal scale (1, discharged/ready for discharge; 7, death) at day 28 was not met in this trial. Among the secondary endpoints, no difference in mortality at day 28 was observed, but time to hospital discharge was shorter in the tocilizumab group. Subgroup analysis suggested there might be a treatment benefit in patients grouped according to their ordinal scale category at baseline.We searched PubMed on September 14, 2020, using the terms “tocilizumab AND (COVID-19 OR coronavirus) AND biomarker” with no language or date restrictions. The search retrieved 18 articles, four of which identified laboratory measures as potential biomarkers in patients who received tocilizumab for the treatment of COVID-19 pneumonia. The biomarkers reported in these studies include interleukin-6, C-reactive protein, ferritin, fibrinogen, liver transaminases, lymphocytes, platelets, and D-dimer. However, these previous studies were single-centre, retrospective, observational studies. Larger, prospective, controlled trials are needed to investigate potential prognostic and predictive biomarkers to assess the outcomes and response to treatments for COVID-19.Added value of this study This exploratory analysis of data from COVACTA demonstrated interleukin-6, C-reactive protein, ferritin, neutrophils (percentage and absolute count), neutrophil-to-lymphocyte ratio, lymphocytes (percentage and absolute count), monocytes (percentage), and platelets as strong prognostic biomarkers in patients hospitalised with severe COVID-19 pneumonia. More important, ferritin showed predictive value for tocilizumab treatment effects on day 28 clinical outcomes of mortality, mechanical ventilation (among the subgroup of patients not receiving mechanical ventilation at randomisation), and clinical status compared with placebo.Implications of all the available evidence In patients with elevated levels of ferritin at baseline, tocilizumab decreased the probability of death, mechanical ventilation, and worsening clinical status at day 28 compared with placebo, suggesting that ferritin might be useful as a predictive biomarker of efficacy outcomes for tocilizumab in patients with severe COVID-19 pneumonia.Competing Interest StatementJennifer Tom and Fang Cai report a grant from the Biomedical Advanced Research and Development Authority (BARDA) to fund the COVACTA trial, are employees of Genentech, and have a patent pending to Genentech for biomarkers for predicting response to an IL-6 antagonist (P36367-US). Min Bao and Larry Tsai report a grant from BARDA to fund the COVACTA study and biomarker analysis, are employees of Roche/Genentech, and have a patent pending for a method for treating pneumonia, including COVID-19 pneumonia with an IL-6 antagonist (EFS ID 38946141). Montserrat Carrasco-Triguero reports a grant from BARDA to fund the COVACTA study and biomarker analysis and is an employee of Genentech. Celia J F Lin, Carrie M Rosenberger, Jacqueline McBride are employees of and own stock/stock options in Genentech. Aditi Qamra and David Summers are employees of Roche. William Stubbings is an employee of F Hoffmann-La Roche AG. Kevin G Blyth, Jordi Carratala, Bruno Francois, Derrick Haslem, Paolo Bonfanti, Nidhi Rohatgi, Lothar Wiese, and Farrah Kheradmand have nothing to disclose. Charles Edouard Luyt reports a grant from Roche to the Institute of Cardiometabolism and Nutrition, Sorbonne Universite, Hopital de la Pitie Salpetriere, Assistance Publique-Hopitaux de Paris for the COVACTA trial and a grant from Correvio and personal fees from Bayer Healthcare, Aerogen, ThermoFisher Brahms, Merck Sharp & Dohme, and Biomerieux outside the submitted work. Thomas Benfield reports grants from Novo Nordisk, Simonsen, GlaxoSmithKline, Pfizer, Gilead, Lundbeck, and Kai Hansen and personal fees from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Gilead, and Merck Sharp & Dohme outside the submitted work. Cor H van der Leest reports personal fees related to the submitted work and personal fees from Bristol Myers Squib, Merck Sharp & Dohme, AbbVie, Boehringer Ingelheim, Roche, and AstraZeneca outside the submitted work. Ivan O Rosas reports a grant from Roche for the COVACTA trial and a grant and personal fees from Genentech/Roche outside the submitted work. Clinical TrialClinicalTrials.gov, NCT04320615Funding StatementThe study was funded by F. Hoffmann-La Roche Ltd and, in part, by federal funds received from the US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201800036C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained for all enrolled patients. The study was conducted in accordance with the International Council for Harmonization E6 guideline for good clinical practice and the Declaration of Helsinki or local regulations, whichever afforded greater patient protection. The protocol was reviewed and approved by all appropriate institutional review boards and ethics committees (see Appendix 1 for the complete list).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). https://vivli.org/ https://vivli.org/members/ourmembers/ https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm